In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer
| Autor: | Barbara LeBlanc, Harriet Streeter, Tanya Dvorak, Kenneth V.L. Rolston, Dah H. Ho |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Microbiology (medical)
Ofloxacin Levofloxacin Microbial Sensitivity Tests Quinolones Gram-Positive Bacteria medicine.disease_cause Microbiology Anti-Infective Agents Ciprofloxacin Neoplasms Gram-Negative Bacteria Streptococcus pneumoniae medicine Humans heterocyclic compounds Pharmacology (medical) Naphthyridines Norfloxacin Antibacterial agent Pharmacology biology biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Trovafloxacin Infectious Diseases Sparfloxacin Viridans streptococci bacteria Fluoroquinolones medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 39:15-22 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/39.suppl_2.15 |
| Popis: | The antibacterial activity of trovafloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin and norfloxacin against bacterial isolates from patients with cancer. In general, the activity of trovafloxacin was comparable to that of ciprofloxacin, levofloxacin and sparfloxacin against most Gram-negative isolates tested (minor differences in the activity of each agent against individual species were seen) and it was the most active agent tested against Stenotrophomonas maltophilia, inhibiting 80% of these isolates at ≤2.0 mg/L. Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin- and methicillin-resistant staphylococci and enterococci. It was much more active than ciprofloxacin against streptococci, including Streptococcus pneumoniae and the viridans streptococci, and was also active against Bacillus cereus and Listeria monocytogenes, inhibiting all isolates at a concentration of ≤0.5 mg/L. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|